| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 658.6 | 554.3 | 537.5 |
| Other income | 4.0 | 3.5 | 15.3 |
| Total income | 662.6 | 557.8 | 552.8 |
| Profit before exceptional items & tax | 131.3 | 98.0 | 112.1 |
| Profit before tax | 131.3 | 98.0 | 112.1 |
| Net profit | 98.3 | 73.3 | 83.8 |
| Operating margin | 19.8% | 17.6% | 20.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +17.30% |
|---|---|
| Net profit, quarter on quarter | +34.10% |
| Revenue, year on year | +22.50% |
| Operating profit, year on year | +31.50% |
| Operating profit, quarter on quarter | +34.70% |
BSE results filing, NSE: SAILIFE. Figures extracted from the filing.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,594.50
- Market cap
- ₹33,879 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 93.7×Sector 42.0×
- Promoter holding
- 34.50%-0.03% QoQ
- FII holding
- 19.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Investor Presentation: Key Takeaways
H1 FY27 revenue ₹1,213 Cr (+17% YoY), EBITDA ₹335 Cr (28% margin), PAT ₹172 Cr (+19%). Q2 revenue ₹659 Cr (+23%). Strategy: integrated CRDMO, larger strategic pharma engagements, ₹621 Cr H1 capex.
Sai Life Science Results Update
Sai Life Sciences posted Q2 FY27 revenue growth of 23% YoY, with H1 PAT up 19% to ₹172 Cr. The company incurred ₹621 Cr capex in H1.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 108,005 ESOP equity shares, taking paid-up capital to Rs.21.26 Crore. No stated consideration means no event value.
Sai Life Science Management Change
Sai Life Sciences appointed three senior management personnel effective 5 November 2026. The appointees include Sidhartha Das as Senior Vice President and Head of Human Resources.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 54,500 equity shares upon the exercise of employee stock options under its ESOP 2008 plan, increasing the total paid-up share capital.
Sai Life Science Other Announcement
Routine quarterly shareholding pattern filing for the quarter ended September 30, 2026, as mandated by SEBI LODR regulations.